A pharmacodynamic study of the optimal P2Y<sub>12</sub> inhibitor regimen for East Asian patients with acute coronary syndrome

Abstract

Short-term administration of 5 mg prasugrel facilitated maintenance within the therapeutic window of OPR compared with the 10 mg prasugrel and ticagrelor groups. Thus, 5 mg prasugrel daily may be the optimal antiplatelet regimen for stabilized East Asian ACS patients.